77 related articles for article (PubMed ID: 15850468)
1. Immunomodulatory effects of selective leucocytapheresis as a new adjunct to interferon-alpha2b plus ribavirin combination therapy: a prospective study in patients with high plasma HCV viraemia.
Sawada K; Masaki N; Hayashi S; Zeniya M; Ishikawa T; Takahashi H; Ohnishi K; Fukunaga K; Hara N; Yamamoto T; Hada T; Toda G
J Viral Hepat; 2005 May; 12(3):274-82. PubMed ID: 15850468
[TBL] [Abstract][Full Text] [Related]
2. Selective granulocyte and monocyte apheresis as a new adjunct to enhance the efficacy of interferon-alpha + ribavirin in patients with high plasma hepatitis C virus.
Sawada K; Kashiwamura S; Okamura H; Ohnishi K; Fukunaga K; Hirata I; Saniabadi A
Dig Liver Dis; 2005 Jul; 37(7):515-21. PubMed ID: 15975539
[TBL] [Abstract][Full Text] [Related]
3. A randomized controlled trial of pegylated interferon alpha-2a (40 KD) or interferon alpha-2a plus ribavirin and amantadine vs interferon alpha-2a and ribavirin in treatment-naïve patients with chronic hepatitis C.
Mangia A; Ricci GL; Persico M; Minerva N; Carretta V; Bacca D; Cela M; Piattelli M; Annese M; Maio G; Conte D; Guadagnino V; Pazienza V; Festi D; Spirito F; Andriulli A
J Viral Hepat; 2005 May; 12(3):292-9. PubMed ID: 15850470
[TBL] [Abstract][Full Text] [Related]
4. The use of different Peg-interferon alpha-2b regimens plus ribavirin in HCV-1b-infected patients after rapid virological response does not affect the achievement of sustained virological response.
Napoli N; Giannelli G; Antonaci A; Antonaci S
J Viral Hepat; 2008 Apr; 15(4):300-4. PubMed ID: 18307592
[TBL] [Abstract][Full Text] [Related]
5. Peginterferon alfa-2b plus ribavirin for the treatment of chronic hepatitis C genotype 4.
Hasan F; Asker H; Al-Khaldi J; Siddique I; Al-Ajmi M; Owaid S; Varghese R; Al-Nakib B
Am J Gastroenterol; 2004 Sep; 99(9):1733-7. PubMed ID: 15330911
[TBL] [Abstract][Full Text] [Related]
6. The preliminary efficacy of interferon-alpha and ribavirin combination treatment of chronic hepatitis C in HIV-infected patients.
Zheng YH; Zhang CY; He Y; Zhou HY; Zou W; Ding PP; Huang L; Li H
Chin Med J (Engl); 2005 Jul; 118(14):1195-200. PubMed ID: 16117865
[TBL] [Abstract][Full Text] [Related]
7. Comparison of a 6-month course peginterferon alpha-2b plus ribavirin and interferon alpha-2b plus ribavirin in treating Chinese patients with chronic hepatitis C in Taiwan.
Lee SD; Yu ML; Cheng PN; Lai MY; Chao YC; Hwang SJ; Chang WY; Chang TT; Hsieh TY; Liu CJ; Chen DS
J Viral Hepat; 2005 May; 12(3):283-91. PubMed ID: 15850469
[TBL] [Abstract][Full Text] [Related]
8. A randomized trial of a 4- vs 12-week daily interferon dose regimen combined with ribavirin in treatment of patients with chronic hepatitis C.
Sarin SK; Goyal A; Kumar S; Guptan RC; Hashmi AZ; Sakhuja P; Malhotra V
Hepatobiliary Pancreat Dis Int; 2004 Feb; 3(1):42-8. PubMed ID: 14969836
[TBL] [Abstract][Full Text] [Related]
9. High-dose interferon alpha-2b induction therapy in combination with ribavirin for Japanese patients infected with hepatitis C virus genotype 1b with a high baseline viral load.
Tsubota A; Arase Y; Suzuki F; Suzuki Y; Akuta N; Hosaka T; Someya T; Kobayashi M; Saitoh S; Ikeda K; Kumada H
J Gastroenterol; 2004; 39(2):155-61. PubMed ID: 15069622
[TBL] [Abstract][Full Text] [Related]
10. Treatment effects and predictors of a 24-week course of interferon alpha-2b plus ribavirin combination therapy for patients with chronic hepatitis C.
Tomimatsu M; Aizawa Y; Chuganji Y; Ishizuka H; Fujita Y; Aizawa R; Abe H; Matsuda T; Itou Y; Nakanishi H; Ushiyama H; Higuchi T; Fujimoto T; Endou H; Iga D; Ohta K; Kuroda H
J Gastroenterol Hepatol; 2006 Jul; 21(7):1177-83. PubMed ID: 16824072
[TBL] [Abstract][Full Text] [Related]
11. Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin for patients with chronic hepatitis C.
Furusyo N; Kubo N; Toyoda K; Takeoka H; Nabeshima S; Murata M; Nakamuta M; Hayashi J
Antiviral Res; 2005 Jul; 67(1):46-54. PubMed ID: 15913800
[TBL] [Abstract][Full Text] [Related]
12. Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT.
Jacobson IM; Ahmed F; Russo MW; Lebovics E; Dieterich DT; Esposito SP; Bach N; Klion F; Tobias H; Antignano L; Brown RS; Gabbaizadeh D; Geders J; Levendoglu H
Am J Gastroenterol; 2004 Sep; 99(9):1700-5. PubMed ID: 15330905
[TBL] [Abstract][Full Text] [Related]
13. Granulocyte and monocyte adsorptive apheresis for patients with chronic hepatitis C virus infection: a report on six cases with high plasma viremia.
Sawada K; Ohnishi K; Fukunaga K; Kusaka T; Ohdo M; Nagase K; Shimoyama T; Hada T
Ther Apher Dial; 2003 Dec; 7(6):547-53. PubMed ID: 15018242
[TBL] [Abstract][Full Text] [Related]
14. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
15. Leucocytapheresis with Adacolumn enhances HCV-specific proliferative responses in patients infected with hepatitis C virus genotype 1.
Diepolder HM; Kashiwagi N; Teuber G; Ulsenheimer A; Franz M; Yokoyama T; Zachoval R
J Med Virol; 2005 Oct; 77(2):209-15. PubMed ID: 16121358
[TBL] [Abstract][Full Text] [Related]
16. Peginterferon alpha-2b plus ribavirin compared with interferon alpha-2b plus ribavirin for initial treatment of chronic hepatitis C in Saudi patients commonly infected with genotype 4.
Alfaleh FZ; Hadad Q; Khuroo MS; Aljumah A; Algamedi A; Alashgar H; Al-Ahdal MN; Mayet I; Khan MQ; Kessie G
Liver Int; 2004 Dec; 24(6):568-74. PubMed ID: 15566506
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of three different regimens for 24 weeks for re-treatment of chronic hepatitis C patients who failed to respond to interferon-alpha monotherapy in Taiwan.
Chuang WL; Dai CY; Chen SC; Lee LP; Lin ZY; Hsieh MY; Wang LY; Yu ML; Chang WY
Liver Int; 2004 Dec; 24(6):595-602. PubMed ID: 15566510
[TBL] [Abstract][Full Text] [Related]
18. A randomized 4-arm multicenter study of interferon alfa-2b plus ribavirin in the treatment of patients with chronic hepatitis C relapsing after interferon monotherapy.
Saracco G; Olivero A; Ciancio A; Carenzi S; Smedile A; Cariti G; Andreoni M; Orsi PG; Biglino A; Tabone M; Roffi L; Croce G; Manca A; Tappero G; Ciccone G; Rizzetto M
Hepatology; 2002 Oct; 36(4 Pt 1):959-66. PubMed ID: 12297844
[TBL] [Abstract][Full Text] [Related]
19. Successful treatment of hepatitis C reinfection with interferon-alpha2b and ribavirin after liver transplantation.
Yedibela S; Schuppan D; Müller V; Schellerer V; Tannapfel A; Hohenberger W; Meyer T
Liver Int; 2005 Aug; 25(4):717-22. PubMed ID: 15998420
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.
von Wagner M; Huber M; Berg T; Hinrichsen H; Rasenack J; Heintges T; Bergk A; Bernsmeier C; Häussinger D; Herrmann E; Zeuzem S
Gastroenterology; 2005 Aug; 129(2):522-7. PubMed ID: 16083709
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
